Ramelteon

Ramelteon
Clinical data
Trade namesRozerem, others
Other namesTAK-375
AHFS/Drugs.comMonograph
MedlinePlusa605038
License data
Dependence
liability		Low
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability1.8%
Protein binding82% (mainly albumin)
MetabolismLiver (CYP1A2 major, CYP2C and CYP3A4 minor)
MetabolitesM-II (active metabolite)
Elimination half-lifeRamelteon: 1–2.6 hours
M-II: 2–5 hours
ExcretionKidney: 84%
Feces: 4%
Identifiers
  • (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]
    furan-8-yl)ethyl]propionamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.215.666 Edit this at Wikidata
Chemical and physical data
FormulaC16H21NO2
Molar mass259.35 g·mol−1
3D model (JSmol)
  • CCC(=O)NCC[C@@H]1CCc2ccc3c(c21)CCO3
  • InChI=1S/C16H21NO2/c1-2-15(18)17-9-7-12-4-3-11-5-6-14-13(16(11)12)8-10-19-14/h5-6,12H,2-4,7-10H2,1H3,(H,17,18)/t12-/m1/s1 checkY
  • Key:YLXDSYKOBKBWJQ-GFCCVEGCSA-N checkY
  (verify)

Ramelteon is a central nervous system (CNS) depressant medication that can help people sleep. It is used for patients that have trouble falling asleep.

Ramelteon has significant drug-drug interaction with the following drugs: amiodarone[*], ciprofloxacin[*], fluvoxamine[*], ticlopidine[*].

References

  1. ↑ Kim, HK; Yang, KI (December 2022). "Melatonin and melatonergic drugs in sleep disorders". Translational and Clinical Pharmacology. 30 (4): 163–171. doi:10.12793/tcp.2022.30.e21. PMC 9810491. PMID 36632077.
  2. ↑ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  3. 1 2 3 4 5 6 7 8 9 "Rozerem- ramelteon tablet, film coated". DailyMed. 28 December 2018. Retrieved 13 April 2020.
  4. ↑ Karim A, Tolbert D, Cao C (February 2006). "Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia". Journal of Clinical Pharmacology. 46 (2): 140–148. doi:10.1177/0091270005283461. PMID 16432265. S2CID 38171735.